Ketorolac S.A.L.F. (Ketorolac Trometamol)

Ketorolac works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the formation of prostaglandins. Reduced prostaglandin levels decrease inflammation and peripheral sensitisation, leading to effective pain relief.

The exact dose and duration are determined by the prescribing clinician based on the patient’s condition, age, renal function and other factors. In practice, adult dosing is often limited to a maximum of five days of therapy to minimise adverse effects.

Safety data for ketorolac during pregnancy and lactation are limited. Because it may affect fetal renal function and prostaglandin pathways, it is generally avoided unless the potential benefit justifies the risk. Breast‑feeding mothers should also consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Ketorolac offers analgesic potency comparable to many opioid agents but without the risk of respiratory depression. Compared with other NSAIDs, it has a higher risk of renal and gastrointestinal adverse effects, so it is usually reserved for short‑term, high‑intensity pain control.

Ketorolac injectable solution should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from direct light, moisture and extreme temperatures. Do not freeze the product, and keep the vial sealed until use.

Ketorolac is given by intramuscular or intravenous injection. The route, volume and rate of administration are determined by the prescriber, who will also monitor the patient for efficacy and any adverse reactions during and after the injection.

The most serious risks include gastrointestinal bleeding, severe renal impairment, cardiovascular events such as myocardial infarction or stroke, and life‑threatening allergic reactions (anaphylaxis). Patients should be monitored closely for signs of these complications, especially when used with other high‑risk medications.

Ketorolac is contraindicated in patients with active peptic ulcer disease, severe renal or hepatic impairment, known hypersensitivity to NSAIDs, recent coronary artery bypass graft surgery, and those receiving anticoagulant therapy where bleeding risk is unacceptable. It should also be avoided in pregnant women near term.